首页> 外文期刊>Journal of Clinical Oncology >Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5

【24h】

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5

机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验，比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2015年第7期|共16页
作者
Fizazi Karim; Jones Robert; Oudard Stephane; Efstathiou Eleni; Saad Fred; de Wit Ronald; De Bono Johann; Cruz Felipe Melo; Fountzilas George; Ulys Albertas; Carcano Flavio; Agarwal Neeraj; Agus David; Bellmunt Joaquim; Petrylak Daniel P.; Lee Shih-Yuan; Webb Iain J.; Tejura Bindu; Borgstein Niels; Dreicer Robert;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [J] . Fizazi Karim, Jones Robert, Oudard Stephane, Journal of Clinical Oncology . 2015,第7期

机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验，比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松
2. Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5 Editorial Comment [J] . Taneja Samir S. The Journal of Urology . 2015,第4期

机译：回复：在基于多西他赛的治疗期间或之后进展为转移性去势抵抗的前列腺癌患者中，III期，双盲，多盲，多中心试验比较了Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松的进展社论评论
3. Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5 Editorial Comment [J] . Taneja Samir S. The Journal of Urology . 2015,第4期

机译：回复：在基于多西他赛的治疗期间或之后进展为转移性去势抵抗的前列腺癌患者中，III期，双盲，多盲，多中心试验比较了Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松的进展社论评论
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Phase III Randomized Double-Blind Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [O] . Karim Fizazi, Robert Jones, Stephane Oudard, -1

机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松
7. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 [O] . Fizazi, K. (Karim), Jones, R. (Robert), Oudard, S. (Stéphane), 2015

机译：III期随机，双盲，多中心试验，在多西他赛为基础的治疗期间或之后，对转移性去势抵抗性前列腺癌患者进行了奥特隆（TAK-700）联合泼尼松与安慰剂联合泼尼松的比较：ELM-PC 5

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号